Search
Ponesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigational[A232079,L32709] Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-phosphate receptor 1 than [fingolimod]. … [A232079] Ponesimod was granted FDA approval on 18 March 2021.[L32709]
Bifeprunox
go.drugbank.com/drugs/DB04888InvestigationalBifeprunox is a novel atypical antipsychotic agent which, along with SLV313, [aripiprazole] and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.
Cyclin-dependent kinase 9
go.drugbank.com/bio_entities/BE0002207TargetHumansThis complex is inactive when in the 7SK snRNP complex form (PubMed:10574912, PubMed:10757782, PubMed:11145967, PubMed:11575923, PubMed:11809800, PubMed:11884399, PubMed:14701750, PubMed:16109376, PubMed … The CDK9/cyclin-K complex has also a kinase activity towards CTD of RNAP II and can substitute for CDK9/cyclin-T P-TEFb in vitro (PubMed:21127351).
Synonyms: Tat-associated kinase complex catalytic subunitProteasome subunit beta type-5
go.drugbank.com/bio_entities/BE0002348TargetHumansWithin the 20S core complex, PSMB5 displays a chymotrypsin-like activity … Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins.
Synonyms: Multicatalytic endopeptidase complex epsilon chainValoctocogene roxaparvovec
go.drugbank.com/drugs/DB15561ApprovedInvestigationalWithdrawn[L43292] Hemophilia A treatments such as prophylactic regimens of exogenous factor VIII or [emicizumab] improve the clinical outcomes of patients but do not eliminate breakthrough bleeding. … [L43282] The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active factor VIII in blood.
Categories: Complex MixturesSynonyms: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)Tafasitamab
go.drugbank.com/drugs/DB15044ApprovedInvestigationalTafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. … [L15302] It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity
Taurolidine
go.drugbank.com/drugs/DB12473ApprovedInvestigationalIt is a derivative of the amino acid [taurine]. … [A263217] In November 2023, a catheter lock solution of taurolidine in combination with [heparin] - marketed as Defencath - received FDA approval under the Limited Population Pathway for Antibacterial
Lactitol
go.drugbank.com/drugs/DB12942ApprovedLactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. … [A190918] It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]).
Categories: Compounds used in a research, industrial, or household settingNemolizumab
go.drugbank.com/drugs/DB15252ApprovedInvestigational[A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169] … Nemolizumab is a humanized monoclonal modified immunoglobulin 2 (IgG2) antibody directed against interleukin-31 receptor alpha (IL-31RA),[L51159] which is an endogenous cytokine implicated in the pathophysiology
Synonyms: Immunoglobulin G2, anti-(interleukin 31 receptor A) (human-Mus musculus monoclonal CIM331 γ-chain), disulfide with human-Mus musculus monoclonal CIM331 κ-chain, dimerLumasiran
go.drugbank.com/drugs/DB15935ApprovedInvestigational[L23554] Lumasiran was granted FDA approval on 23 November 2020.[L23394] … Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1).